How will new medications affect the lipoprotein apheresis situation in Germany?

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 71-72

  Parhofer, K G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anacetrapib; Lipoprotein apheresis; Lomitapide; Mipomersen; PCSK9 antibodies

Indexed keywords

ANACETRAPIB; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; TRIACYLGLYCEROL;

APHERESIS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; FAMILIAL HYPERCHOLESTEROLEMIA; FLU LIKE SYNDROME; GAIN OF FUNCTION MUTATION; GERMANY; HUMAN; INJECTION SITE REACTION; LIPID APHERESIS; LIVER FATTY DEGENERATION; LIVER FUNCTION TEST; PRIORITY JOURNAL; SIDE EFFECT;

BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; GERMANY; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN(A); LIPOPROTEINS; TREATMENT OUTCOME;

EID: 84872875086     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.022     Document Type: Article

References (10)

1. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681.
2. Catapano A.L., Reiner Z., De B.G., et al. ESC/EAS Guidelines for the management of dyslipidaemias the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217(1):3-46.
3. Thompson G.R., Barbir M., Davies D., et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010, 208(2):317-321.
4. Parhofer K.G. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid 2012, 7:29-38. Epub; 2012 May 31.
5. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354(12):1264-1272.
6. Stein E.A., Mellis S., Yancopoulos G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012, 366(12):1108-1118.
7. Cuchel M., Bloedon L.T., Szapary P.O., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007, 356(2):148-156.
8. Cannon C.P., Shah S., Dansky H.M., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010, 363(25):2406-2415.
9. Stein E.A., Dufour R., Gagne C., et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012 Nov 6, 126(19):2283-2292.
10. Parhofer K.G., Vogt A. Mipomersen and apoB synthesis inhibitor evaluation of potential to reduce necessity for lipid-apheresis in patients with heterozygous FH and CAD. Atherosclerosis 2011, 12:159.